Beta Drugs cash flow

·UnclassifiedChart ›
Latest FY26
Cash from operations
₹37.3cr+18.0% on FY25
Capital spending
₹53.5cr+45.1% on FY25
Free cash flow
−₹16.2cr−₹5.3 cr in FY25
Cash from financing
−₹8.1cr₹118 cr in FY25
₹ crore except per share
Tap a line for its trendLast 12Mto Sep 2026FY26Mar 2026FY25Mar 2025
Adjustments to reconcile profit — non-cash items
—0.012.5
—15.37.0
—17.20.0
Changes in working capital
—−14.7−10.0
——−23.3
—−16.6—
—−5.7−1.5
——12.0
—9.4—
—0.63.8
——−19.0
Cash from operating activities
70.154.457.0
—5.50.5
—59.957.5
—−9.9−5.1
—−12.7−20.8
——31.6
—37.331.6
Cash from investing activities
—50.332.5
—3.14.3
—7.84.0
—9.95.1
——−35.7
—−51.4−35.7
Cash from financing activities
—−0.1—
——0.5
—6.3124
—6.00.0
—15.30.0
—7.0−7.0
——118
—−8.1118
—−22.2114
—−22.2114
Reference items
92.375.774.6
20.8%19.7%20.6%
−16.2−16.2−5.3
−₹15.98−₹15.98−₹5.18
—0.90×0.75×
—15.3—
Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

BETA₹1,849.70

Beta Drugs Limited

· Unclassified
₹ CrorePeersTHEJOMACPOWERSAKARSERVOTECHMcap ₹1,875 Cr
View
In ₹ Crore except Per Share
12 Months Ending
FY25
31/03/2025
FY26
31/03/2026
Last 12M
30/09/2026
Adjustments to Reconcile Profit — Non-cash Items
+ Depreciation & Amortisation12.50.0—
+ Finance Costs7.015.3—
+ Other Non-cash Items0.017.2—
Changes in Working Capital
+ Inventories-10.0-14.7—
+ Trade Receivables-23.3——
+ Trade Receivables — Current—-16.6—
+ Other Current Assets-1.5-5.7—
+ Trade Payables12.0——
+ Trade Payables — Current—9.4—
+ Other Current Liabilities3.80.6—
Total Working Capital Changes-19.0——
Cash from Operating Activities
Profit Before Tax (per I/S)57.054.470.1
+ Total Adjustments (incl. Working Capital)0.55.5—
Cash from Operations (pre-tax)57.559.9—
+ Interest Received — Operating-5.1-9.9—
+ Other Inflows / (Outflows) — Operating-20.8-12.7—
Cash from Operating — before Extraordinary Items31.6——
Cash from Operating Activities31.637.3—
Cash from Investing Activities
+ Acq of Fixed Assets (Capex)32.550.3—
+ Acq of Intangible Assets4.33.1—
+ Loans & Advances Made4.07.8—
+ Interest Received — Investing5.19.9—
Cash from Investing — before Extraordinary Items-35.7——
Cash from Investing Activities-35.7-51.4—
Cash from Financing Activities
+ Proceeds from Issue of Shares—-0.1—
+ Proceeds from Issue of Shares (unclassified)0.5——
+ Proceeds from Borrowings124.46.3—
+ Repayment of Borrowings0.06.0—
+ Interest Paid0.015.3—
+ Other Inflows / (Outflows) — Financing-7.07.0—
Cash from Financing — before Extraordinary Items117.9——
Cash from Financing Activities117.9-8.1—
Net Changes in Cash (pre-FX)113.8-22.2—
Net Changes in Cash113.8-22.2—
Reference Items
EBITDA74.675.792.3
EBITDA Margin %20.5919.6720.78
Free Cash Flow (CFO − Capex)-5.3-16.2-16.2
Free Cash Flow per Basic Share-5.18-15.98-15.98
Cash Flow to Net Income0.750.90—
Cash Paid for Interest—15.3—
As filed, sign as filed: a payment tagged as a positive magnitude in the filing stays positive here, so read the label, not the sign. A line appears only when the company tagged that concept in at least one period shown — depth follows the filer, so a thin statement means a thin filing. Total Adjustments is the filer's own grand total of the reconciliation and spans BOTH the non-cash items and the working-capital block; Profit Before Tax plus it equals Cash from Operations (pre-tax). It can be reported when its components are not, so it is never a sum of the rows above it. No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.